---
title: "Cartalax"
canonical_url: https://peptidelibrary.app/library/cartalax
description: "Ala-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series, marketed for cartilage and connective-tissue research. Like others in the series it is proposed to act by influencing transcription in the tissue it is associated with, a hypothesis supported almost entirely by cell-culture and cytogenetic work from one research group. No controlled clinical evidence exists for joint or cartilage outcomes, and it is not FDA-approved."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Cartalax

Cartalax (also called Cartilage bioregulator or AED) is a khavinson bioregulator. Cartalax is Ala-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with cartilage and connective tissue. The proposed mechanism, shared across the series, is that the peptide reaches the nucleus and binds specific DNA promoter sequences, influencing transcription of genes governing chondrocyte protein synthesis.

Ala-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series, marketed for cartilage and connective-tissue research. Like others in the series it is proposed to act by influencing transcription in the tissue it is associated with, a hypothesis supported almost entirely by cell-culture and cytogenetic work from one research group. No controlled clinical evidence exists for joint or cartilage outcomes, and it is not FDA-approved.

Also known as: Cartilage bioregulator, AED.

Categories: Muscle/Recovery, Experimental.

## Classification

- Type: Khavinson bioregulator / research
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Cartalax is Ala-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with cartilage and connective tissue. The proposed mechanism, shared across the series, is that the peptide reaches the nucleus and binds specific DNA promoter sequences, influencing transcription of genes governing chondrocyte protein synthesis. The evidence consists of cell-culture and cytogenetic studies from one research group, published mainly in Russian-language journals. Controlled clinical evidence in cartilage or joint outcomes is absent, and no receptor-mediated pathway has been characterised.

Targets: Chondrocytes (proposed).

Origin: Synthetic short peptide bioregulator.

## Properties

- Sequence: Ala-Glu-Asp
- Length: 3
- Molecular formula: C12H19N3O7
- Molecular weight: 317.3 g/mol
- CAS number: 85806-95-7
- Half-life: Short (hours)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 1
- Latest source: 2019

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019. 2019. Preclinical: in vitro (cells or tissue). Population: Human periodontal ligament stem cells in culture. GAP43 and nestin expression increased with the four-peptide combination and with KED alone. An independent effect of AED on those markers was not reported. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/30791821/)

## Safety

Side effects: Not well characterized.

Risks: Research-only.

Contraindications: Hypersensitivity.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Cartalax is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Cartalax?

Ala-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series, marketed for cartilage and connective-tissue research. Like others in the series it is proposed to act by influencing transcription in the tissue it is associated with, a hypothesis supported almost entirely by cell-culture and cytogenetic work from one research group. No controlled clinical evidence exists for joint or cartilage outcomes, and it is not FDA-approved.

### What are the side effects of Cartalax?

Cartalax has no controlled human safety data, so its side-effect profile is not well established. No specific adverse effects are well documented. Cautions recorded on this profile: hypersensitivity. This is reference information, not medical advice.

### How does Cartalax work?

Cartalax is Ala-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with cartilage and connective tissue. The proposed mechanism, shared across the series, is that the peptide reaches the nucleus and binds specific DNA promoter sequences, influencing transcription of genes governing chondrocyte protein synthesis.

### Is Cartalax FDA approved?

No. Cartalax is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Cartalax?

Reported half-life for Cartalax is Short (hours). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Cartalax?

Cartalax has the sequence Ala-Glu-Asp, giving a chain of 3 amino acids. Its molecular formula is C12H19N3O7.

### What peptides are similar to Cartalax?

Compounds most often compared with Cartalax include Bonomarlot, Bronchogen, Cardiogen and Cerluten. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002](https://pubmed.ncbi.nlm.nih.gov/12374906/)
- [Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001](https://pubmed.ncbi.nlm.nih.gov/11713572/)
- [Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010](https://pubmed.ncbi.nlm.nih.gov/19830585/)
- [Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002](https://pubmed.ncbi.nlm.nih.gov/12170291/)
- [Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019](https://pubmed.ncbi.nlm.nih.gov/31099784/)
